10.22376/ijpbs.2019.10.1.p1-12 Volume 11 Issue 1 2020 (January-March) Urinary Tract Infections (UTIs) are a major reason of illness in infant boys, older men and females of all ages. Severe sequelae embrace persistent recurrences, pyelonephritis with sepsis, renal damage in young children, preterm birth and complications caused by frequent usage of antimicrobial agents including high-level antibiotic resistance and lessThan i greaterThan Clostridium difficile lessThan /i greaterThan colitis. Thus, a test product "CV-HFU01" was developed by Climic Health Pvt. Ltd, with the objective to assess its usefulness for the management of recurrent UTI. It was an open label, single arm, prospective, interventional clinical study. The subjects were advised to consume 1 tablet of CV-HFU01 twice daily orally before meal with water for 3 months. The change in symptoms of UTI; Patients Global Assessment; Physician's global Assessment; safety of CV-HFU01 tablets was determined by assessing the adverse events and tolerability of CV-HFU01 tablet. CV-HFU01 was significantly effective in relieving symptoms associated with recurrent UTI like change in symptoms like burning micturition, intermittent urination, pain during urination and other symptoms of UTI. The results revealed that subjects undergoing the treatment duration of 90 days but in first 30 days 80% subjects presented complete recovery from all the symptoms related to UTI. CV-HFU01 was safe and effective alternative in the management of recurrent UTI. DR. VEENA DEO, BHUSHAN SHRIKHANDE, GAYATRI GANU AND DR. TANUJA PANCHABHAI CV-HFU01, Recurrent UTI, Single arm, Open label, Patients Global Assessment 74-83